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Alan Brooks1,2*, Thomas A Smith1,2, Don de Savigny1,2 and Christian Lengeler1,2Abstract
Background: It is unclear how long it takes for health interventions to transition from research and development
(R&D) to being used against diseases prevalent in resource-poor countries. We undertook an analysis of the time
required to begin implementation of four vaccines and three malaria interventions. We evaluated five milestones
for each intervention, and assessed if the milestones were associated with beginning implementation.
Methods: The authors screened World Health Organization (WHO) databases to determine the number of years
between first regulatory approval of interventions, and countries beginning implementation. Descriptive analyses of
temporal patterns and statistical analyses using logistic regression and Cox proportional hazard models were used
to evaluate associations between five milestones and the beginning of implementation for each intervention. The
milestones were: (A) presence of a coordinating group focused on the intervention; (B) availability of an
intervention tailored to developing country health systems; (C) international financing commitment, and; (D) initial
and (E) comprehensive WHO recommendations. Countries were categorized by World Bank income criteria.
Results: Five years after regulatory approval, no low-income countries (LICs) had begun implementing any of the
vaccines, increasing to an average of only 4% of LICs after 10 years. Each malaria intervention was used by an
average of 7% of LICs after five years and 37% after 10 years. Four of the interventions had similar implementation
rates to hepatitis B vaccine (HepB), while one was slower and one was faster than HepB. A financing commitment
and initial WHO recommendation appeared to be temporally associated with the beginning of implementation.
The initial recommendation from WHO was the only milestone associated in all statistical analyses with countries
beginning implementation (relative rate = 1.97, P < 0.001).
Conclusions: Although possible that four milestones were not associated with countries beginning
implementation, we propose an alternative interpretation; that the milestones were not realized early enough in
each intervention’s development to shorten the time to beginning implementation. We discuss a framework built
upon existing literature for consideration during the development of future interventions. Identifying critical
milestones and their timing relative to R&D, promises to help new interventions realize their intended public health
impact more rapidly.
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The GAVI Alliance (GAVI; formerly the Global Alliance
for Vaccines and Immunization) and the Global Fund to
Fight AIDS, Tuberculosis and Malaria (GFATM) were
established in 2000 and 2002, respectively. Since then,
they have committed more than USD 20 billion to ad-
dress the divergence in health status and access to health
interventions between developed and developing coun-
tries (DCs). In parallel, the past decade has seen unpre-
cedented investments in research and development
(R&D) for new health interventions for use in develop-
ing countries; approximately USD 3.2 billion was
invested in 2009 alone, an increase of 8.2% from 2008
[1]. Product development partnerships (PDPs) have
grown in number and are focused on developing drugs,
rapid diagnostic tests, vaccines and other interventions
for developing countries [2]. The use of such interven-
tions might eventually be subsidized by GAVI, GFATM,
and other financing mechanisms.
It is normal in R&D for a large percentage of candi-
date interventions to fail during development. However,
the investments above will lead to some new interven-
tions being approved by regulators and becoming avail-
able for use. A critical step is then how quickly they will
begin to be implemented through national health sys-
tems of developing countries. Beginning implementation
does not guarantee, but is on the critical path to, inter-
ventions becoming widely accessible to people in need
in developing countries.
The progression from R&D to implementation
through national health systems in developing countries
can be broken down into a series of stages and parallel
activities, although it may vary somewhat by type of
intervention (Figure 1). An intervention moves from
R&D through a series of international and ultimately na-
tional policy decisions about use and financing. These
decisions lead to the beginning of implementation,Figure 1 New interventions: From R&D to implementation (illustrative
**WHOPES: WHO Pesticide Evaluation Scheme.scaling-up over months or years to target levels, and
ideally access as defined below. Regulatory, manufactur-
ing, and supplemental study activities take place in par-
allel. The World Health Organization (WHO) plays a
critical role, such as reviewing interventions to deter-
mine if they are suitable for purchase by agencies of the
United Nations (UN) [3,4]. Figure 1 presents a process
following a linear progression for clarity, however this
may rarely be the actual case. The process varies accord-
ing to the unique scientific, policy and other challenges
of each intervention.
Access has been defined as the result of a set of coor-
dinated activities needed to ensure that interventions
will ultimately have an equitable public health impact
[5]. A number of authors have studied access independ-
ently. Obrist et al. (2007) proposed an access framework
focusing on consumer decisions, livelihood, and the
assets of poor populations with regard to health inter-
ventions [6]. They reviewed five concepts determining
access to health interventions: availability, accessibility,
affordability, adequacy, and acceptability. Mahoney et al.
(2007) identified four criteria for access to new vaccines:
availability; affordability; acceptability; and adoptability
[7]. They propose an access framework that acknowl-
edges the role of decisions made during the R&D period
on later implementation. PDPs generally agree on a
similar set of access criteria relevant to many interven-
tions [5,8].
Frost & Reich (2008) analyzed the history of access to
six health interventions in the developing world: prazi-
quantel; hepatitis B vaccine; malaria rapid diagnostic
tests; Norplant; vaccine vial monitors; and female con-
doms [8]. They proposed that access depends on activ-
ities related to four key factors: architecture, availability,
affordability, and adoption. Architecture encompasses
the organizational structures and relationships that co-
ordinate activities addressing availability, affordability). *Drugs, Vaccines Diagnostics, Reproductive health supplies.
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description of the R&D phase of each intervention, not-
ing that developer choices are important for later policy
decisions on use and implementation. Each concept
Mahoney et al. (2007), Obrist et al. (2007), and PDPs
use in their access frameworks is consistent with the
ones identified by Frost & Reich [5-8]. For example,
Obrist’s et al. concept of acceptability is consistent with
Frost and Reich’s “end-user adoption and appropriate
use”. The one exception, which is not relevant to na-
tional implementation of an intervention and therefore
this analysis, is Obrist et al.’s adequacy concept, match-
ing health service organization with individual client
expectations [6].
These analyses of access are complemented by many
analyses of strategies for the implementation of single or
closely-related interventions [9,10]. Some of the litera-
ture focuses on the R&D period, including how clinical
trials and regulatory processes impact implementation
[11-15]. Much of the literature focuses on the periodFigure 2 Frost and Reich’s (2008) access framework. The figure presen
that availability, affordability and adoption considerations are addressed for
relationship established with the purpose of coordinating and steering the
of making, ordering, shipping, storing, distributing, and delivering a new he
end-user. Affordability: Ensuring that health technologies and related servic
Gaining acceptance and creating demand for a new health technology fro
and individual patients. The concept of “acceptability” is inherent in “End-U
graphic above to illustrate this framework’s consistency with the work of o
Noncommercial-Share Alike 3.0 License [8].after regulatory approval, using qualitative [7,16-25] and
quantitative approaches [26-30] (Table 1).
This paper hypothesizes that five high-level mile-
stones, consistent with the research on access above, are
associated with developing countries beginning imple-
mentation of interventions. If these milestones are asso-
ciated, it follows that they could be targets of efforts by
those developing new interventions in order for imple-
mentation to begin, and access to be achieved, more
quickly. This paper explores this hypothesis by analyzing
how long it took after regulatory approval, or equivalent,
for countries to begin implementing each of seven inter-
ventions, and related implementation to when each of
these five milestones took place for each intervention.
Methods
The number of years between initial approval of seven
interventions by a stringent regulatory body and the
beginning of implementation, considered to be the first
year of reported use by each country through itsts access as depending on a coordinating architecture that ensures
an intervention. Architecture: Organizational structures and
availability, affordability, and adoption activities. Availability: Logistics
alth technology to ensure it reaches the hands (or mouths) of the
es are not too costly for the people who need them. Adoption:
m global organizations, government actors, providers and dispensers,
ser Adoption and Appropriate Use” but was made explicit in the
ther authors. Reproduced under a Creative Commons Attribution-
Table 1 Considerations affecting access to new interventions
Relevance to access Considerations
Prior to regulatory
approval
Availability & Affordability Design of interventions specifically for the needs of DCs [31-37]
Adoption Clinical studies to address questions unique to DCs [12,38-42]
Requirements for international policy recommendations [43,44]
Preparing for country decision-making processes [45]
After regulatory
approval
Coordinated action Coordination between stakeholders [16]
Availability Alignment of intervention with the unique needs of
developing country health systems [16,18,19,23,24]
Forecasting and manufacturing plans incorporating DCs, [16,21]
Adapted procurement mechanisms [16,21]
Affordability Affordability, financing, & cost-effectiveness [16,18,19,21-24,27-30]
Adoption Research aligned with policy-maker needs, including burden of
disease addressed by an intervention [18,21-24,29]
Importance of international technical consensus and
recommendations, including influence of neighboring countries [21,23,46]
Strengthened national processes, acceptability, and/or governance [17,19-21,26]
Legend: Pubmed and Web of ScienceW databases were searched for full names or abbreviations of hepatitis B, Haemophilus influenzae type B, pneumococcal
conjugate, rotavirus, insecticide-treated net, rapid diagnostic test, or artemisinin-based combination therapies AND (malaria or vaccin*) AND (develop* OR
decision* OR policy* OR adopt* OR implement*).
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data. Similar but more limited analyses have been ap-
plied to health interventions previously [16,47,48]. In
addition, the timing of each of five hypothesized mile-
stones was determined for each intervention. Descrip-
tive and statistical analyses were used to assess
associations between the timing of milestones and
countries beginning implementation.
The year of approval by a stringent regulatory authority
was intended to reflect the earliest time point at which it
would have been ethical to begin implementation on a
large scale outside of a controlled trial. This is especially
critical for vaccines and drugs because of the issues of
safety and quality. Some interventions, such as ITNs, while
generally not overseen by regulatory authorities, have
mechanisms in place for reviewing safety and more re-
cently quality, which were considered as equivalent to the
time of regulatory approval for this analysis [49,50]. In
these cases, efficacy and effectiveness may be evaluated
through the establishment of a scientific consensus be-
tween experts on the basis of existing trial experience
[51,52].
Countries were categorized as low- (LIC), lower-middle-
(LMIC), upper-middle- (UMIC), and high-income (HIC)
according to the World Bank stratification, correspond-
ing respectively to 2009 gross national income per
capita of $995 or less, $996 - $3,945, $3,946 - $12,195,
and $12,196 or more [53]. World Bank data were used
as they provide a standardized categorization for coun-
tries, and are used by the GFATM in determining sup-
port to countries.Estimating time from regulatory approval, or equivalent,
to beginning implementation
Vaccines
Four vaccines were selected for inclusion in the study
based on their public health importance, diversity in year
of availability, similar ages of target populations and
comparable delivery strategies. The diseases they target —
hepatitis, pneumonia, meningitis, and diarrhea— are
among the world’s leading causes of mortality and mor-
bidity, especially in developing countries. Hepatitis B
(HepB) and Haemophilus influenzae type b (Hib) vaccines
have been available for decades while pneumococcal con-
jugate (PC) and rotavirus (RV) vaccines are among the
newest.
The regulatory approval of the first rotavirus vaccine
was a unique case. Licensed in 1998, it was removed
from the market in 1999 due to concerns about intus-
susceptions (a potentially life threatening telescoping of
the intestine within itself ). A new rotavirus vaccine was
licensed in 2004 in Mexico although WHO did not con-
sider its NRA fully functional. The vaccine was then
licensed by the European Medicines Agency (EMA) in
2006 [54]. This analysis considered 2006 to be the year
of the rotavirus vaccine’s first stringent regulatory ap-
proval, although the history is considered further in the
discussion.
WHO collects reports from 193 countries each year in
order to assess vaccine implementation [55] (Table 2).
These data were used to generate tables showing the
first year of vaccine use and the number of years until
coverage matched that of the third dose of diphtheria-
Table 2 Characteristics of countries included in the analysis and summary of responses
Included in
sample
High-
income
Upper-
middle-
income
Lower-
middle-
income
Low-
income
No income
category
Intervention
implemented
(%)
Not
implemented
Did not
respond
Hepatitis B vaccine 193 50 46 54 40 3 180 (93%) 13 0
Haemophilus influenzae
type B vaccine
193 50 46 54 40 3 163 (84%) 30 0
Rotavirus vaccine 193 50 46 54 40 3 30 (16%) 163 0
Pneumococcal vaccine 193 50 46 54 40 3 61 (32%) 132 0
Insecticide-treated
mosquito net
104 4 21 39 40 0 89 (86%) 0 15
Rapid diagnostic test 104 4 21 39 40 0 40 (38%) 6 58
Artemisinin-based
combination therapy
104 4 21 39 40 0 63 (61%) 12 29
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given to the same infant population at the same times as
the other vaccines in this analysis. WHO’s data cover the
years 1989–2009 for HepB, 1991–2009 for Hib, and
2008–09 for PC and RV. Data for the remaining years
through March, 2011 and for missing dates in the WHO
data were taken from the Vaccine Information Manage-
ment System (VIMS), a database maintained at the
International Vaccine Access Center, Johns Hopkins
University [56].Malaria interventions
Malaria was selected for inclusion as it is one of the
major causes of mortality and morbidity in children, and
preventive, therapeutic and diagnostic interventions are
available. Insecticide-Treated Nets (ITNs) and more re-
cently developed Long-Lasting Insecticidal Nets (LLINs)
prevent malaria. In this paper, “ITN” is used for both
ITNs and LLINs. Immuno-chromatographic rapid diag-
nostic tests (RDTs) allow diagnosis of malaria with min-
imal training and hence are valuable for optimizing
treatment strategies. Artemisinin-based combination
therapies (ACTs) are the current standard for malaria
treatment.
In the absence of a formal regulatory structure, regula-
tory approval of ITNs was based on a WHO expert
committee concluding they were safe for individuals,
and therefore could be used outside clinical trials [49].
For RDTs, regulatory approval was considered to be the
point at which the first RDT became available in the
developed world where there are strong quality assur-
ance systems.
WHO provided data on country implementation in
104 malaria-endemic countries, taken from the 2010
survey of countries by the Global Malaria Program as
part of the annual World Malaria Report [57] (Table 2).
The survey asked respondents to identify the yearWHO-recommended malaria policies began to be imple-
mented. Respondents indicated the first year “ITNs dis-
tributed to all age groups” or “ITNs distributed free of
charge”. For diagnostic tests, respondents indicated the
first year “RDTs used in communities”, and for
artemisinin-based combination therapies they indicated
the first year “ACT is free of charge for under 5 years
olds in the public sector” or “ACT is free to all”. Non-
response to the specific questions about implementing
the interventions, while other questions in the survey
were answered, was classified as not implementing the
intervention. Fourteen percent of countries did not re-
spond for the ITN questions, 56% for RDTs, and 28% for
ACTs. The earliest date was used in cases where differ-
ent dates were given for each policy or if parts of coun-
tries (e.g. mainland Tanzania versus Zanzibar) reported
different dates.Five hypothesized milestones
Milestones consistent with and thought to be important
to coordination, availability, affordability and adoption
were hypothesized from the literature above (Table 1).
This is not to suggest that these hypothesized milestones
addressed all aspects of each access concept, nor that
they always happened in a specific sequence. The timing
and source document for each milestone is summarized
in Table 3.Milestone A - Coordinating architecture
The establishment of an organization or international
partnership focused on supporting development, estab-
lishment of technical consensus around, and/or use of
the intervention was considered consistent with a co-
ordinating architecture. Hep B, Hib, PC, RV, RDT, and
ACT were supported by product-development partner-
ships. ITNs were supported by the Roll Back Malaria
Partnership.
Table 3 Hypothesized access milestones for each intervention
Regulatory
approval
A) Coordinating
group
B) Improved
intervention
C) Financing
commitment
D) Initial WHO
recommendation
E) Comprehensive WHO
recommendation
HepB 1982 1986 1996 2000 n/a 1992
Hib 1988 1998 1997 2000 1998 2006
RV 2006 2003 2008 2007 2007 2009
PC 2000 2003 2009 2007 n/a 2007
ITN 1991 1998 2001 2002 1995 2007
RDT 1995 2003 n/a 2002 2006 2010
ACT 1999 1999 2009 2002 2002 2006
Legend.
Data sources below relate to the column number for each intervention. Websites were accessed on April 14, 2011 unless otherwise indicated.
Hepatitis B vaccine: Regulatory approval) [58]; A) [59]; B) Personal communication, Marie-Claude Dubois, April 11, 2011; C) [60]; D) n/a; E) [61].
Haemophilus influenzae type b vaccine: Regulatory approval) [43]; A) [62]; B) Personal communication, Marie-Claude Dubois, April 11, 2011; C) [63]; D-E) [43].
Rotavirus vaccine : Regulatory approval) [54]; A) [64]; B) [65]; C) [66]; D-E) [43].
Pneumococcal conjugate vaccine: Regulatory approval) [43]; A) [64]; B) [67]; C) [66]; D) n/a; E) [43].
Insecticide-treated mosquito net: Regulatory approval) [49]; A) [68]; B) [50]; C) [69]; D) [70]; E) [51].
Rapid diagnostic test: Regulatory approval) [71]; A) [8,72]; B) n/a; C) [69]; D) [73]; E) [72].
Artemisinin-based combination therapy: Regulatory approval) [74]; A) [75]; B) [76,77]; C) [69]; D) [74]; E) [78].
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health systems
Each vaccine and two of the malaria interventions were
improved over time to better align with the needs of
DCs. The year a new version of each intervention that
was intentionally designed to meet the needs of DCs was
approved by regulators, or equivalent, was considered
relevant for availability. HepB and Hib antigens were
combined with the widely implemented DTP vaccines to
create new “four in one” or “five-in-one” vaccines. New
versions of pneumococcal conjugate vaccines included
additional serotypes prevalent in the developing world
and improved packaging. New rotavirus vaccines
decreased the size of packaging, required two doses in-
stead of the traditional three, and were more heat stable.
ITNs were replaced by LLINs, and an ACT specifically
formulated and packaged for use in infants was devel-
oped after the initial tablet formulation. No major
improvements in RDTs were identified over the course
of their deployment. VIMS provided information on
product presentation and formulation of Hib in most
countries, used in this analysis to consider if the speed
of scaling-up changed when the presentation of the vac-
cine was better aligned with the needs of DCs.Milestone C - Financing commitment
A major global financing commitment by an inter-
national organization was considered important for af-
fordability to countries to begin implementation. All of
the interventions have been supported by such financing.
From 2000, GAVI supported 72 to 75 countries with less
than $1000 gross national income (GNI)/capita to pur-
chase and implement vaccines. From 2011, it increased
the threshold to $1500 GNI/capita decreasing eligibility
to 56 countries due to inflation. For malaria control, theGFATM is by far the most important donor, supporting
low and middle income countries.Milestones D and E - WHO recommendations
Recommendations by WHO to use each intervention
were considered important for international-level support
for adoption. WHO issued an initial, limited recommen-
dation and then a more comprehensive recommenda-
tion some years later for five of the interventions. The
timing of the initial recommendation was milestone D,
while the comprehensive WHO recommendation was
milestone E.Statistical analysis
The year of country implementation of each intervention
was extracted from the selected global databases into
Microsoft Excel, and back-validated against the original
databases for accuracy. Cox proportional hazard models
were used to compare the rates of beginning implemen-
tation of interventions between countries, as functions
of the intervention and income group of the country.
The analysis for each country started with the year when
the intervention was approved by a stringent regulatory
authority, or equivalent. The data were treated as right-
censored where the country had not introduced the
intervention during the periods described previously. In
this analysis the adoption rate corresponds to the hazard
in a conventional survival analysis. Plots of the cumula-
tive baseline hazard over time were used to assess time
trends in the underlying rate of beginning implementa-
tion, allowing for the covariates of income level and
milestones described previously. These analyses were
carried out using the PHREG procedure in SAS (SAS In-
stitute Inc., Cary, NC, USA, version 9.2 for Windows).
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Years to beginning implementation
The implementation of all interventions is presented in
Table 4 for low and lower-middle-income countries after
5, 10 and 15 years. A decade after each studied vaccine
or malaria intervention was approved by regulators, 33%
or fewer low and lower-middle-income countries, and in
most cases less than 15%, had begun to implement it.
The exception was ACTs which 70% of low and 56% of
lower-middle-income countries had begun to implement
after 10 years.
The mean of the percentage of low-income countries
beginning implementation of each intervention after five
years was 3% and 20% after 10 years. However, malaria
interventions were implemented sooner than vaccines, a
mean percentage of 37% of countries at 10 years com-
pared with only 4% for vaccines. No low-income country
implemented any of the new vaccines in the first five
years.
The mean of the percentage of lower-middle-income
countries beginning implementation of each intervention
after five years was 6% and 24% after 10 years. However,
malaria interventions were implemented sooner than
vaccines, a mean percentage of 35% of countries at
10 years compared with only 12% for vaccines. Figure 3
shows the cumulative percentages of countries beginning
implementation of each intervention, by number of years
after regulatory approval and for each income group.
HepB, Hib and ITNs are approaching universal imple-
mentation, having been implemented by more than 80%
of countries (Table 2). The mean time was 12.2 years
across all malaria-endemic countries to begin imple-
menting ITNs, and 14.6 years for Hib and 16.7 years for
HepB across all countries (Table 5). Beginning imple-
mentation in low-income countries took an average of
12.2 years for ITNs, 18.8 years for Hib vaccine andTable 4 Percentage of LICs and LMICs implementing interven
5 years
LIC LM
Hepatitis B 0% 6%
Haemophilus influenzae type B 0% 0%
Rotavirus 0% 15%
Pneumococcal 0% 0%
Insecticide-treated mosquito nets 3% 5%
Rapid diagnostic test 0% 3%
Artemisinin-based combination therapy 18% 15%
Average Vaccines 0% 5%
Average Malaria 7% 8%
Average All 3% 6%
Legend.
LIC = Low-income countries; LMIC = Lower-middle-income countries.21.2 years for HepB vaccine as compared to 15.0, 9.0
and 13.2 years in high-income countries.
Figure 4 presents the cumulative implementation of
each intervention by countries, stratified by income
group. Twenty-seven years after HepB vaccine was first
approved, 93% of countries had begun to implement it
for routine infant use, with low income countries
appearing to accelerate implementation after GAVI
began to provide financial support. A few HICs in Europe
recommend it instead for adolescents or high-risk indivi-
duals. It has taken more than 20 years for 90% of low-
income countries to use Hib, with implementation in LICs
appearing to accelerate after a comprehensive WHO
recommendation. The lowest coverage of Hib (76% of
countries) was in the lower-middle-income countries,
many of which are too wealthy to receive financing from
GAVI.
For rotavirus vaccines, 15-20% of high, upper-middle,
and lower-middle-income countries had begun to imple-
ment it after five years, an equality across country in-
come levels that did not occur for other vaccines. It took
more than 10 years for Hib and pneumococcal vaccines
to reach a similar proportion of lower-middle-income
countries. Upper-middle-income countries appear to
have implemented Hib and pneumococcal vaccines in
the same proportions, with the first countries beginning
implementation after seven years and reaching approxi-
mately 20% of countries at ten years. No low-income
country had implemented rotavirus vaccine as of March
2011, more than five year after regulatory approval,
which appears consistent with HepB, Hib, and PC vac-
cines where low-income early adopters did not begin im-
plementation until 8–10 years after the vaccines were
available.
Malaria interventions were initially implemented by
similar proportions or a slightly higher proportion oftions after 5, 10, and 15 years
10 years 15 years
IC LIC LMIC LIC LMIC
3% 24% 10% 41%
3% 0% 15% 26%
– – – –
5% 13% – –
30% 33% 95% 72%
10% 15% – –
70% 56% – –
4% 12% – –
37% 35% – –
20% 24% – –
Figure 3 Proportion of implementing countries over time in each income category, stratified by intervention. The figure presents the
proportion of countries implementing each intervention by year since regulatory approval. Panel A=High income countries; B=Upper middle
income countries; C= Lower middle income countries; D= Low income countries. Color code: Hepatitis B vaccine (HepB) = Blue; Haemophilus
influenzae type b vaccine (Hib) =Dark red; Rotavirus vaccine (RV) = Green; Pneumococcal vaccine (PC) = Purple; Artemisinin-based combination
therapy (ACT) = Light red; Insecticide-treated mosquito net (ITN) =Orange; Rapid diagnostic test (RDT) = Black.
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ITNs and ACTs began to be used in notably greater pro-
portions of low-income than wealthier countries. After
12 years, a greater proportion of low-income countries
had begun implementing RDTs than wealthier countries.
These findings are consistent with the differences in dis-
ease burden in these countries, with higher levels in the
poorest countries.
There were significant statistical differences in rates of
beginning implementation between interventions relative
to hepatitis B vaccine in high income countries (likelihood
ratio statistic (LRS): 30.6; 6 degrees of freedom (d.f.);
P < 0.001, adjusted for effects of income level and of the
different milestones) (Table 6). ACTs was the fastest inter-
vention to begin implementation, with a rate 2.41 times
that of HepB (95% CI 1.38-4.21) (Table 6). Rotavirus is
being implemented at 1.99 times that of HepB, but the
confidence interval is wide and includes zero (95% CI
0.85-4.66). The slowest was RDTs with a rate of 0.54 (95%Table 5 Mean number of years (range) until countries began
High-income Upper- middle- in
Hepatitis B 13.3 (1–25) 16.9 (6–24)
Haemophilus influenzae type B 9.0 (3–17) 14.3 (8–23)
Insecticide-treated mosquito net 15.0 (14–16) 12.9 (4–18)
Legend.
The table shows data only for the three interventions which more than 80% of all c
implement.CI 0.33-0.88). Hib, PC, and ITNs all had similar rates to
HepB.
There was a highly significant difference between level
of income of countries and the rate of beginning imple-
mentation (LRS 27.2; 3 d.f.; P < 0.0001), this difference
being almost entirely accounted for by the difference be-
tween high income countries and the others. There was
very little difference in rates between the different cat-
egories of middle income countries, or between middle
and low income countries (Table 6); each of these cat-
egories was associated with rates of beginning imple-
mentation only just over half that of high income
countries.
Milestones
Table 3 summarizes milestones for each intervention.
Figure 4 indicates when each milestone from Table 3
was reached relative to regulatory approval (i.e. time
zero). Patterns of temporal associations between accessimplementation, by income group
come Lower- middle- income Low- income All countries
16.0 (1–26) 21.2 (8–27) 16.7 (1–27)
17.5 (11–22) 18.8 (10–22) 14.6 (3–23)
11.7 (1–18) 12.2 (5–16) 12.2 (1–18)
ountries (HepB, Hib), or malaria-endemic countries (ITNs), have begun to
Figure 4 (See legend on next page.)
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(See figure on previous page.)
Figure 4 Beginning implementation of each intervention by countries, by income group, including hypothesized milestones. Panels
A-G present the proportion of countries beginning to implement each intervention by year since the year of regulatory approval. Panel
A=Hepatitis B vaccine; B=Haemophilus influenzae type b vaccine; C= Rotavirus vaccine; D= Pneumococcal conjugate vaccine; E= Insecticide-
treated mosquito net; F= Rapid diagnostic test; and G=Artemisinin-based combination therapy. For vaccines, countries are stratified according to
World Bank income groups: High= Blue dotted line; Upper- middle = Red short dashed line; Lower- middle =Green long dashed line;
Lower = Purple line. Malaria-endemic countries are stratified by low income versus all other endemic countries. LICs = Purple line; Other endemic
countries = Red dash and dot line. Year of regulatory approval (year 0) is provided in the bottom left hand corner of each panel. Ar indicates
establishment of a group providing coordination (i.e. architecture). II indicates availability of an improved intervention better aligned with the
needs of developing countries. Fi indicates year of a global financing commitment, such as through GAVI or GFATM. IR indicates year of initial
WHO recommendation. CR indicates year of comprehensive (e.g. global) WHO recommendation.
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plementation, can be drawn from Figure 4.
Milestone A - Coordinating architecture
A coordinating architecture was put in place years prior
to significant beginning of implementation, except for
Hib and ITNs. Coordination was in place years before
comprehensive WHO recommendations were made in
all situations, and prior to initial WHO recommenda-
tions in all cases except for that of ITNs. It was also in
place before a financing commitment in all cases, except
RDTs and before an improved intervention in all cases
except Hib.
Milestone B - Intervention designed for developing country
health systems
Less than 10% of low-income countries began imple-
mentation of any of the vaccines prior to an improved
intervention being available. No lower or upper-middle-Table 6 Relative rates of beginning implementation by
intervention and country income (Cox proportional
hazard)
Rate of
beginning
implementation
95%
confidence
interval
Haemophilus influenzae
type B vaccine
0.81 (0.60-1.08)
Rotavirus vaccine 1.99 (0.85-4.66)
Pneumococcal vaccine 1.18 (0.70-1.98)
Insecticide-treated mosquito nets 0.96 (0.68-1.34)
Rapid diagnostic test 0.54 (0.33-0.88)
Artemisinin-based
combination therapy
2.41 (1.38-4.21)
Low-income 0.51 (0.40-0.64)
Lower-middle-income 0.56 (0.44-0.70)
Upper-middle-income 0.52 (0.41-0.67)
Legend.
Rates of beginning implementation are calculated relative to the rate of
beginning HepB implementation in high income countries in the absence of
any of the facilitating milestones. All likelihood ratio statistics (interventions
having 6 degrees of freedom and income groups having 3) testing these
effects were highly significant, with P < 0.001.income countries began implementing Hib prior to
availability of an improved vaccine, but up to 40% of
countries were already implementing HepB and 10-20%
were implementing rotavirus and/or pneumococcal vac-
cines. For HepB and Hib vaccines it was possible to esti-
mate the average time from beginning implementation
until coverage matched DTP3 levels (data not shown).
After combination vaccines became available in 1997,
which allowed the antigens to be administered in a sin-
gle injection with DTP, countries required approximately
one year less for coverage to be scaled-up to match DTP
than it did prior to a combined vaccine. Improved mal-
aria interventions became available after 30-70% of
countries had already begun implementing each type of
intervention. These data suggest that many LMICs,
UMICs and HICs did not wait for an improved, second-
generation vaccine prior to starting implementation.
And that once the second generations were available,
they may have been scaled-up more rapidly. Countries
frequently did not wait for improved malaria interven-
tions before beginning implementation.
Milestone C - Financing commitment
There was a sharp increase in the proportion of low-
income countries beginning implementation of HepB
and Hib vaccines and low and lower-middle-income
countries implementing pneumococcal vaccines after
GAVI’s advent and associated financing commitments.
There was a similar increase in the proportion of coun-
tries, particularly low-income, beginning implementation
of malaria interventions after GFATM’s advent and asso-
ciated financing commitments. For ITNs and Hib, finan-
cing commitments came after an initial WHO
recommendation, but before a comprehensive recom-
mendation. RDT financing came before any recommen-
dation, and for RV, PC and ACTs, a recommendation
and financing came in the same year. A financing com-
mitment generally preceded a sharp increase in the pro-
portion of countries beginning implementation.
Milestones D and E - WHO recommendations
The proportion of countries beginning implementation
of HepB, Hib, PC, ITNs, and ACTs did not accelerate in
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until after a WHO recommendation. Comprehensive
WHO recommendations for use of the malaria interven-
tions did not come until 40% or more of low-income
countries had begun to implement the interventions,
while for HepB, RV and PC, comprehensive recommen-
dations came prior to any significant implementation
in LICs.
Figure 5 shows the number of years from regulatory
approval to initial and/or comprehensive WHO recom-
mendation, and financing commitment, with the inter-
ventions listed in order from earliest to most recent year
of regulatory approval. Five interventions had initial
recommendations, which took a mean of 5.8 years
(range 1–11). The additional time for those five inter-
ventions to receive a comprehensive recommendation
was a mean of 6.0 years (range 2–12). HepB and PC had
no initial recommendations, requiring 10 and 7 years re-
spectively for WHO to issue comprehensive recommen-
dations. For all seven interventions, the average time
from regulatory approval to comprehensive recommen-
dation was 10.9 years, with a range of 3–18 years. On
average it took 8.4 years, with a range of 1–18 years,
from regulatory approval to a financing commitment.
The time required from regulatory approval to policy
recommendations and financing commitments has
decreased over the 22 year period represented by the
interventions.
An initial proportional hazard model analyzed the rela-
tive rates associated with each of the milestones separ-
ately, adjusting for levels of income groups of countries
and interventions. Initial WHO recommendation (relativeFigure 5 Time from regulatory approval to WHO recommendation an
earliest to most recent year of regulatory approval. The year of regulatory a
Dark blue bars indicate the number of years to an initial recommendation,
comprehensive recommendation. Green bars indicate the number of yearsuptake rate 1.83; 95% confidence interval (CI) 1.26-2.64),
coordinating group (relative uptake rate 2.19; CI 1.45-
3.30), and financing commitment (relative uptake rate
1.78; CI 1.30-2.45) were all positively associated in this
analysis, suggesting these where associated with countries
beginning implementation earlier than occurred for HepB.
On the other hand, a comprehensive WHO recommenda-
tion (relative uptake rate 0.45; CI 0.33-0.61) was negatively
associated, suggesting it was associated with countries
taking longer to begin implementation than with HepB.
Availability of an improved intervention seemed to have
little effect on the rate of beginning implementation
(relative uptake rate 0.86; CI 0.62-1.18). Since the timing
of these milestones was unlikely to be independent, a
further analysis was conducted in which the effects were
fitted simultaneously to adjust for possible confounding
(Table 7). In this analysis the estimated effect sizes were
similar to those in the unadjusted analysis, while the
only statistically significant milestones were the positive
effect of initial WHO recommendation (1.97. 95% CI
1.33-2.94), and the association of a comprehensive
WHO recommendation with a slowing down of begin-
ning implementation relative to HepB (0.45; 95% CI
0.31-0.64).
Plots of the rate of beginning implementation (i.e. rate
of adoption; cumulative baseline hazard from the Cox
model) for analysis including only high income countries
(Figure 6A), suggested a more or less linear increase
with time. This corresponds to a constant underlying
rate of beginning implementation, once the effects of the
different milestones are allowed for. In contrast, the cu-
mulative baseline hazard for low income countriesd financing, by intervention. Interventions are presented from
pproval and intervention name are indicated below each set of bars.
when relevant, while light blue bars indicate the number of years to a
to a financing commitment.
Table 7 Effects of hypothesized access milestones on rate of beginning implementation (Cox proportional hazard)
Relative rate of
beginning
implementation
95%
confidence
interval
Likelihood
ratio statistic
P-value
Coordinating group 1.20 (0.74-1.95) 0.6 0.5
Improved intervention 0.85 (0.59-1.22) 0.8 0.4
Financing commitment 1.24 (0.88-1.75) 1.5 0.2
Initial WHO recommendation 1.97 (1.33-2.94) 11.2 <0.001
Comprehensive WHO recommendation 0.45 (0.31-0.64) 19.1 <0.001
Legend.
Adoption rates are calculated relative to the rate of adoption of HepB vaccine in high income countries.
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vention had been available, indicating a tendency for
interventions to be more likely to be implemented the
longer they were available, even allowing for the effects
of the milestones.Discussion
This paper analyzed the time between regulatory ap-
proval and beginning implementation of seven interven-
tions; four vaccines and three malaria interventions. The
interventions target diseases responsible for a substantial
proportion of the overall global burden of disease, par-
ticularly for children in developing countries. According
to WHO, each of these interventions should target a
similar group of children, and be used globally in all
countries or all malaria-endemic countries. We hypothe-
sized that five milestones, consistent with the literature onFigure 6 Effect of time since regulatory approval on rate of
beginning implementation. The vertical axis shows the rate of
beginning implementation (i.e. adoption) of interventions according
to the number of years since regulatory approval. All interventions
are included, except where too few countries were relevant to the
analysis, as noted below. The grey area indicates the 95%
confidence region around the result. A. High income countries only.
Analysis includes all interventions except those against malaria. B.
Low income countries only. Analysis includes all interventions
except rotavirus vaccination.access to interventions, were associated with the begin-
ning of implementation in developing countries.
We found that during the five years after regulatory
approval, interventions began to be used in only a tiny
minority of developing countries. After 10 years, less
than 1/3 of low and lower-middle-income countries had
begun to use interventions. ACTs were the exception,
being implemented earlier than the other interventions,
likely due to the evolving crisis as resistance grew to
antimalarial treatments. Even so, one may question if
implementation of ACTs was fast enough. Vaccines and
ITNs continue to be implemented in developing coun-
tries at approximately the same pace as HepB in the
1980s and 1990s, while RDTs are being implemented
slower than HepB.
There is no international agreement on how quickly
new interventions should be implemented. One option
is to suggest that they should be introduced with min-
imal delay relative to the pace in high income countries.
But that overlooks the much greater burdens of disease
and numbers of lives lost in low income countries.
These interventions should be implemented as fast as or
faster than HICs. It is also hopeful that there appear to
be shorter delays between regulatory approval and policy
and financing decisions for more recent interventions.
However, the history for RV, the most recent interven-
tion, is more tangled than the more linear processes of
the other interventions. During 2011, there was substan-
tial, growing momentum through GAVI for use of rota-
virus and pneumococcal conjugate vaccines [79]. This
momentum cannot save the lives already lost over the
many years that these vaccines have been available and
not implemented, but hopefully the proportion of imple-
menting countries will accelerate as suggested in
Figure 6B.
The initial WHO recommendation and a financing
commitment were most temporally associated with in-
creasing the percentage of countries beginning imple-
mentation. A coordinating architecture was in place
years before an increase in the percentage of countries
beginning implementation for five of the interventions,
suggesting it may contribute to but not trigger
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not wait for an improved intervention or a comprehen-
sive WHO recommendation. This suggests that activities
strengthening country decision-making may accelerate
implementation.
Statistically, only the initial WHO recommendation
was associated with beginning implementation in all
analyses. This may not be surprising as countries and fi-
nancing bodies often follow WHO’s guidance. This sug-
gests that those developing new interventions should
work systematically to anticipate the research questions
WHO and international organizations, including finan-
cing bodies, will need addressed to make policy deci-
sions. A more comprehensive WHO recommendation
was associated with slower implementation. Wealth
impacted implementation, differentiating high-income
countries from all the developing countries which began
implementation at slower, more similar rates.Challenges and limitations to the analysis
The analysis focuses on implementation of interventions
through national health systems as a way of reaching
enough people to achieve an equitable public health im-
pact, consistent with the definition of access. Future ana-
lyses could consider ways to reflect private sector
provision, which is relatively modest for vaccines but
can be significant for malaria interventions. Analyses
could also consider ways that political pressure and ad-
vocacy inform and influence decisions (this may have es-
pecially speeded up the introduction of ACTs), such as
through key opinion leaders or the media.
The analysis did not consider country characteristics
apart from income group, given that each of the inter-
ventions has been recommended for use globally. The
analysis is also likely to be conservative, understating the
delays, given that it focused on beginning of implemen-
tation, not the time to reach nation-wide coverage.
Coverage is already analyzed by WHO and others else-
where [57,80].
Data used in the analysis are imperfect. However, we
found no evidence of a systematic reporting gap or bias
from any group of countries. Imperfect data were par-
tially offset by including every country in the world.
The only relatively small income group was HIC
malaria-endemic countries, of which there are only four
(Table 2). It is important to recognize that countries
can choose not to implement any intervention, or use
one in a different fashion which may not be captured
in databases. Data on the year of beginning implemen-
tation of interventions ideally would be taken from
multiple sources (e.g. surveys, WHO, national data.)
Multiple sources would be particularly important if the
analysis focused on coverage rates, for which preciseestimates are difficult to confirm [28]. Using few data
sources was mitigated by limiting the analysis to the
year of beginning implementation, a single time point
which should be more reliably reported. Relying pri-
marily on WHO data also has the benefit of limiting
variability associated with incorporating data from dif-
ferently designed studies.
We combed a broad selection of literature to establish
the timing of milestones for each intervention. The mile-
stones for rotavirus vaccine and ITNs were perhaps the
most challenging. As noted in the methods, a RV vaccine
was first approved in 1998 and then withdrawn by the
manufacturer due to safety concerns. A new rotavirus
vaccine was licensed by Mexico in 2004, an NRA that
was not considered by WHO to be fully functional, and
began to be implemented in Latin America. It was
licensed by the EMA in 2006. It may be the case that
the availability of a licensed vaccine from 1998 to 1999,
and a new vaccine licensed by some countries from 2004
accelerated milestones and implementation planning.
However it is also possible that the safety questions and
shadow over RV vaccines slowed milestones and imple-
mentation. ITNs were deemed safe for use in 1991,
which was considered the point of regulatory approval
for this analysis. However, the first recommendation for
use of ITN’s based upon demonstrated efficacy was
made by WHO in 1995 for Africa [70]. International
organizations did not develop a shared commitment to
initiate large scale implementation of ITNs until 1997
and later. Bias due to investigator judgment was mini-
mized by scrupulous attention to documentation of
sources (Table 3).
There is no reason to assume that the pattern of delays
in the adoption of vaccines and malaria interventions is
unique. It is possible that the delays for other interven-
tions are longer than those for immunization and mal-
aria, which enjoy a relatively high profile within public
health arenas.A revised hypothesis for accelerating access
One interpretation of the study’s findings is that the null
hypothesis was disproved only for the initial WHO
recommendation. However, the temporal associations
and existing literature suggest caution in asserting that
all the other milestones were not associated with devel-
oping countries beginning to implement interventions.
An alternative interpretation, preferred by the authors, is
that these milestones could be associated with countries
beginning implementation if they took place earlier in
the development and implementation of an intervention.
And that by taking place earlier, they could shorten and
increase the efficiency of the transition from R&D to
decision-making and implementation (Figure 1).
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be evaluated as new interventions are being developed.
The hypothesis suggests that organizations need to begin
working systematically on access-related issues earlier
on, during the R&D stages, in order to shorten the time
to begin implementation and realize equitable access in
developing countries. Carefully paced activities during
R&D could lead to decision-making processes at inter-
national and country levels and milestones being
achieved shortly after regulatory approval, as has been
proposed recently for malaria vaccines [81,82].
Figure 7 builds on Frost and Reich’s (2008) access
framework. It proposes additional activities specifically
intended to take place prior to regulatory approval and
thereby accelerate the beginning of implementation and
eventual access. It must be noted that there are risksFigure 7 Proposed access framework incorporating R&D and implem
framework as shown in Figure 2. Other areas are new to the framework. Ac
space above the black strip, “Regulatory Approval”, while actions carried ou
space below. Area in grey is reproduced under a Creative Commons Attribto planning for access during the R&D phase. Interven-
tions can always fail due to safety, efficacy or other
considerations.
The R&D process requires a coordinated, long-term
and systematic approach to associated access activities;
an approach which is specific to each intervention’s con-
text. Available interventions need to be tailored to fragile
developing country health systems and their users, and
scientific questions resolved to facilitate eventual imple-
mentation. Affordability-related decisions during R&D
seek to minimize future purchase and implementation
costs, and incorporate interactions with international fi-
nancing bodies, such as GAVI and the GFATM, years
before funds are required. Adoption activities relate to
planning by international organizations to identify and
ensure that information needed for normative guidanceentation periods. The area in grey represents the original access
tions that take place during the R&D period are described in the
t in the decision and implementation period are described in the
ution-Noncommercial-Share Alike 3.0 License [8].
Brooks et al. BMC Public Health 2012, 12:683 Page 15 of 17
http://www.biomedcentral.com/1471-2458/12/683and policy recommendations are developed at pace with,
or as part of, clinical development [43].
A number of other activities that directly inform, and
that may be directly informed by, access activities are
reflected in the proposed framework. Regulatory over-
sight of clinical trials extends throughout R&D and
evolves into regulatory monitoring and pharmacovigi-
lance in the implementation period. Pre-clinical and
clinical studies lead into phase four effectiveness studies
and operational research. Epidemiological, economic and
modeling studies may relate broadly to a disease area
and/or may directly inform decisions on use of a specific
intervention.Conclusion
The analysis in this paper suggests that 10 years or more
after a proven life-saving public health intervention
becomes available, only a small fraction of countries in
need in the developing world is likely to have access to
it. As a result, lives are being lost unnecessarily. Invest-
ments in carrying out high-quality clinical trials and
regulatory processes as fast as possible are at risk of
being wasted. During this extended period, manufac-
turers may be left with idle capacity or may decide to ex-
clude low and lower-middle-income countries entirely
from their supply plans, in favor of more reliable mar-
kets in high-income countries.
This paper hypothesizes that the international commu-
nity can accelerate implementation and access by sys-
tematically addressing access-related topics during the
R&D period of new interventions. Such an approach
raises challenges for organizations, asking them to iden-
tify ways they can contribute to new interventions dur-
ing R&D, anticipating and beginning to address likely
bottlenecks in advance. Identifying the key areas for
early foresight in the development process has the po-
tential to significantly shorten the time elapsed before
developing countries benefit from new interventions,
and as a consequence, reduce the unnecessary disease
and loss of life that is experienced today.
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